HIV and Malaria drug clinical trial for COVID-19 will stop- WHO


The World Health Organization (WHO) announced Saturday that it will stop trials on some possible COVID-19 drugs. It announced that HIV and Malaria drug clinical trials will stop. 

The WHO mentioned that the said drugs failed to reduce the mortality for novel coronavirus patients. The said medications are hydroxychloroquine and lopinavir/ritonavir. 

READ: Coronavirus disease (COVID-2019) situation reports

Authorities found grounds to halt clinical trials when the highest single day increase of COVID-19 cases happened. In a single day, the WHO recorded about 200,000 additional cases. 

Of the 212,326 new cases last Friday, 53,213 came from the United States of America.

Solidarity Trial’s International Steering Committee reported that the said drug had little or no improvement to the mortality rates of patients. Hence, the UN Health Agency adapted the said recommendation. 

The WHO said that, “These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care.” 

“Solidarity trial investigators will interrupt the trials with immediate effect,” WHO said in a statement, referring to large multi-country trials that the agency is leading,” it added. 

Other than HIV and Malaria drug

One branch of clinical trials is looking into Gilead’s antiviral drug. The European Committee has given the said drug conditional approval. It claimed that the medication shortened hospital recovery time. 

When it started, the health authority started trying five approaches. The said interventions are: standard care; remdesivir; hydroxychloroquine; lopinavir/ritonavir; and lopanivir/ritonavir combined with interferon.

The WHO director general Tedros Adhanom Ghebreyesus said that participants were already gathered for the study.

He said that they have recruited 5,500 patients in 39 countries. The health agency will release the interim results within two weeks. 

On a grander scheme, medical experts are currently developing about 150 treatments for the disease. They have put at least 18 under experimental treatment.

Recent Articles